AstraZeneca's triple whammy of good news pleases market
Friday 30 July 2010
AstraZeneca pleased the market with a triple dose of good news yesterday as it won endorsement in the United States for its new blood-thinning drug Brilinta, reported strong results and doubled its share buyback programme.
The Anglo-Swedish group is expecting annual sales of more than $1bn (£640m) from Brilinta. Its prospects were boosted yesterday when the US Food and Drug Administration (FDA) advisory panel gave initial backing for the treatment.
It voted 7-1 in favour of approving the treatment, despite some unfavourable trial data, and Brilinta being tested on a relatively low number of patients in the US.
Details of the FDA vote came as AstraZeneca reported a better-than-expected 5 per cent increase in core profits in the second quarter, to $3.53bn. The performance was helped by generic competitors being slow to copy a number of off-patent drugs, including the blockbuster ulcer treatment, Nexium.
AstraZeneca's chief executive officer, David Brennan, said: "Our second-quarter performance reflects continued strong growth in our emerging markets and good performance for key brands Crestor, Seroquel and Symbicort."
The second-quarter results led the group to double the size of its $1bn share-buyback programme, which was announced in January to "[recognise] that some earnings fluctuations are to be expected as the company's revenue base transitions through this period of exclusivity losses and new product launches." The positive updates pushed the group's shares up by 86.5p to 3,289p.
Despite the results, and the comments from the FDA, a number of industry analysts were cautious on AstraZeneca's longer-term prospects. The results were "the last pre-key-patent-expiry set of results for AstraZeneca, with Brilinta's recommendation the last of the significant expected positive newsflow," said Collins Stewart's analyst, Emmanuel Papadakis.
The group is the UK's second-biggest drug-maker behind GlaxoSmithKline and acknowledges that it has been slow at bringing new drugs to development, a problem exacerbated by its ageing portfolio of current medicines.
"We haven't been as productive as we would have liked to have been in the last few years and for a pharmaceutical company, that's pretty significant, right?" Mr Brennan said in a recent interview with The Independent.
"I would like to see sustainable delivery on a consistent basis from our research and development organisation, and that's why they have been set a goal: from the beginning in 2010, on average, we will bring two new products to the market each year. That's our goal and that's what I want to be measured against," he added.
- 1 Australia to impose 24-hour curfew on all cats to protect endangered species
- 2 Model's video shoot on the beach interrupted by sudden landing of a group of illegal migrants
- 3 The difference between a psychopath and a sociopath
- 4 Black and ethnic minority people twice as likely to be hit by Tory cuts than white people, report finds
- 5 MH370 search: Boeing 777 wing that could match missing plane found on the French island of Reunion
Kate Winslet thanked 'particularly horrible' girl who bullied her at school after Titanic success
Australia to impose 24-hour curfew on all cats to protect endangered species
Israel accused of killing 75 children during day of 'carnage' and war crimes in Gaza war
MH370 search: Boeing 777 wing that could match missing plane found on the French island of Reunion
Madeleine McCann 'not the identity' of fair-haired girl found dead in suitcase in Australia
Yvette Cooper: Our choice is years of Tory rule under Jeremy Corbyn – or a return to a Labour government
Labour leadership contender Jeremy Corbyn says 'we can learn a great deal from Karl Marx'
I am the Jeremy Corbyn supporter that many will tell you doesn't exist
Public anger after French sunbather beaten up by gang for wearing a bikini in Reims park
Labour leadership: New poll shows party is now even 'less electable' than under Ed Miliband
Labour leadership contest: I would never quit the party, says Liz Kendall
iJobs Money & Business
£45 - £55k DOE: Guru Careers: A Financial Controller is required to join a suc...
£12500 - £20000 per annum: Recruitment Genius: Scotland's leading life insuran...
£22500 - £24500 per annum: Recruitment Genius: Inbound and outbound calls with...
£18000 - £40000 per annum: Recruitment Genius: This fast growing Insurance Bro...